Chemotherapy for Pancreatic Cancer can be Optimized with the Use of Drug Resistance Testing Using Tissue Organoids

Objective: The purpose of the present investigation was to ascertain how drug resistance in pancreatic cancer organoids affects efficacy chemotherapy. Study Design: Retrospective study Place and Duration: Jinnah International hospital, Abbottabad, 15th March- September, 2022 Methods: A total 72 patients both genders with were presented this study. After obtaining written consent from participants, we recorded detailed demographic information about them, including their age, sex, body mass index. Pathological evaluation tumour regression grade (TRG) compared data on dose schedule neoCTx treatment. SPSS 22.0 used analyze all data. Results: This had 43 (59.7%) males 29 (40.3%) females. 22 (30.6%) aged between 18-30 years, 25 (34.7%) 31-40 15 (20.8%) 41-50 10 (13.9%) aged> 50 years. In a CTx-naive PDO lines, 8 showed distinct response FOLFIRINOX or Gem/Pac. As much as 34.7 per cent NeoCTx PDOs experienced an unfavorable reaction neoadjuvant Modified treatments which lowest successful individual medicine eliminated full regimen no meaningful change response. Conclusion: It is possible that testing CTx-nave PDAC will help determine optimal adjuvant treatment regimens. order increase proportion completing course treatment, it may be beneficial individualize poly-chemotherapy regimens by removing chemicals low effectiveness. Keywords: Pancreatic Cancer, Chemotherapy, Drug Resistance, Tissue Organoids